By screening for these contaminants in blood, doctors might be able to more easily and quickly diagnose pancreatic cancer. In turn, earlier detection might trigger more rapid, effective treatment before malignancy cells spread beyond this organ. The latest analysis centers around glypicin-1, a compound in the bloodstream that some experts say can provide as a biomarker for the condition. This biomarker within the blood is elevated in both breast and pancreatic cancer patients. The hope here is to carry out further researcher into GPC1 and find if a straightforward blood test could possibly be generated to greatly help doctors more easily detect – and subsequently deal with – pancreatic cancer. What sort of test might arise from the study remains unclear soon.The agreement provides multiple incentives for BCA-member bloodstream centers to make use of Haemonetics' suite of innovative blood management software items, including Interlude and Prelude, portion of the Haemonetics' integrated Symphony suite of items, along with eQue automated interview and evaluation donor screening system. ‘We have been delighted with this contract which gives tangible benefits for current and potential prospects,’ stated Janet Conneely, Vice President and General Supervisor of Haemonetics' Software program Solutions Division. ‘We realize that our clients are challenged to boost the donor knowledge, throughput, price per collection and general resource efficiency of their bloodstream centers. Because the global head in blood administration solutions, you can expect a varied suite of products which includes devices, it platforms, and business providers for blood enthusiasts.